The differential vulnerability of striatal projection neurons in 3-nitropropionic acid-treated rats does not match that typical of adult-onset Huntington's disease

Experimental Neurology

Volumn 176, Issue 1, 2002, Pages 55-65

  Sun, Z ^a   Xie, J ^a   Reiner, A ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

3 nitropropionic acid; Basal ganglia; Enkephalin; Huntington's disease; Neurodegeneration; Substance P

Indexed keywords

3 NITROPROPIONIC ACID; SUCCINATE DEHYDROGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; ENERGY METABOLISM; ENTOPEDUNCULAR NUCLEUS; GLOBUS PALLIDUS; HUNTINGTON CHOREA; IMAGE ANALYSIS; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

EID: 0036318336     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.2002.7947     Document Type: Article

References (63)

1. Alternative excitotoxic hypotheses
2. Striatal and nigral neuron subpopulations in rigid Huntington's disease: Implication for the functional anatomy of chorea and rigidity-akinesia
3. Genetic and molecular biology of Huntington's disease
4. Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease
5. 3-Nitropropionic acid's lethal triplet: Cooperative pathways of neurodegeration
6. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease
7. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illness?
8. Energetics in the pathogenesis of neurodegenerative diseases
9. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid
10. A detailed examination of substance P in pathologically graded cases of Huntington's disease
11. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases?
12. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid
13. Somatostatin and neuropeptide Y concentration in pathologically graded cases of Huntington's disease
14. Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington's disease
15. Age dependence of striatal neuronal death caused by mitochondrial dysfunction
16. Mutation of a nuclear succinate dehydrogenase gene result in mitochondrial respiratory chain deficiency
17. Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat
18. Systemic administration of 3-nitropropionic acid: A new model of Huntington's Disease in rat
19. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates
20. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid
21. Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia
22. Transcriptional dysregulation in Huntington's disease
23. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease
24. Selective sparing of a class of striatal neurons in Huntington's disease
25. Relative survival of striatal projection neurons and interneurons after intrastriatal injection of quinolinic acid in rats
26. Age-dependent differences in survival of striatal somatostatin - NPY - NADPH - Diaphorase-containing interneurons versus striatal projection neurons after intrastriatal injection of quinolinic acid in rats
27. Relative resistance of striatal neurons containing calbindin or parvalbumin to quinolinic acid-mediated excitotoxicity compared to other striatal neuron types
28. Energy and glutamate dependency of 3-nitropropionic acid neurotoxicity in culture
29. Mitochondria in neurodegeneration: Acute issechmia and chronic neurodegenerative diseases
30. 3-Nitropropionic acid produces indirect excitotoxic damage to rat striatum
31. Mechanisms of 3-nitropropionic acidtoxicity
32. The basal ganglia
33. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease
34. Inhibition of succinate dehydrogenase by malonic acid produces an "excitotoxic" lesion in rat striatum
35. Mitochondrial defect in Huntington's disease caudate nucleus
36. Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production
37. Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid
38. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
39. Mitochondrial toxin 3-nitropropionic acid produces startle reflex abnormalities and striatal damage in rats that model some features of Huntington's disease
40. Pattern of cell loss in Huntington's disease
41. Striatal glucose consumption in chorea free subjects at risk of Huntington's disease
42. Mitochondrial dysfunction in the pathogenesis of necrotic and apoptotic cell death
43. Huntington's disease: New approach to an old problem
44. Transient global ischemia in rats yields striatal projection neuron and interneuron loss resembling that in Huntington's disease
45. NeuN, a neuronal specific nuclear protein in vertebrates
46. Mitochondria in neurodegeneration: Bioenergetic function in cell life and death
47. Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: Implications for neuroprotection studies
48. Chronic 3-nitro-propionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease
49. Temporal profile of neuronal damage in a model of transient forebrain ischemia
50. Differential loss of striatal projection neurons in Huntington's disease
51. Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients
52. Huntington disease and the related disorder, dentatorubral-pallidoluysian atrophy (DRPLA)
53. Differential distribution of nicotinamide adenine dinucleotide phosphate-diaphorase and neural nitric oxide synthase in the rat choroid plexus: A histochemical and immunohistochemical study
54. Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low-grade of Huntington's disease using high-resolution image analysis
55. Increased apoptosis of Huntington's disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization
56. Mitochondrial impairment reduces the threshold for in vivo NMDA-mediated neuronal death in the striatum
57. Neurochemical substrates of rigidity and chorea in Huntington's disease
58. 3-Nitropropionic acid neurotoxicity in organotypic striatal and corticostriatal slice cultures is dependent on glucose and glutamate
59. Biochemical abnormalities and excitototoxicity in Huntington's disease brain
60. NADPH-diaphorase: A selective histochemical marker for the cholinergic neurons of the pontine reticular formation
61. 3-Nitropropionic acid induces a spectrum of Huntington's disease-like neuropathology in rat striatum
62. Huntington Disease
63. Neuropathological classification of Huntington's disease